Last reviewed · How we verify

NCT07036887

Effectiveness of 1st Rib Mobilization and Scalene Muscles Muscle Energy Technique Among Patients With Asthma

Active, enrolled EARLY_PHASE1 Last updated 25 June 2025
What this trial tests

EARLY_PHASE1 trial testing First Rib Mobilization + Respiratory Physiotherapy in Asthma in 47 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
4 March 2025
Primary endpoint
1 June 2025
30 September 2025

Quick facts

Lead sponsorSuperior University
PhaseEARLY_PHASE1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposehealth services research
Enrollment47
Start date4 March 2025
Primary completion1 June 2025
Estimated completion30 September 2025
Sites1 location across Pakistan

Drugs / interventions tested

Conditions studied

Sponsor

Superior University

Who can join

Adults 18 to 65, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This randomized controlled trial aims to evaluate the effectiveness of first rib mobilization and scalene muscle energy technique (MET) in improving respiratory function and reducing symptoms in patients with asthma. Asthma is a chronic inflammatory condition of the airways characterized by bronchoconstriction, airway hyperresponsiveness, and mucus overproduction, often leading to respiratory difficulty and increased use of accessory muscles such as the scalene.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

Other Superior University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07036887.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing